Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Selinexor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    XPOVIO® Gains Reimbursement Approval in 2nd-Line Multiple Myeloma
    XPOVIO® Gains Reimbursement Approval in 2nd-Line Multiple Myeloma

    01 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xpovio-receives-reimbursement-approval-in-south-korea-for-a-second-multiple-myeloma-indication-302700200.html

    PR NEWSWIRE
    01 Mar 2026
    Share Share
    Karyopharm Reveals 2025 Financials, Highlights Company
    Karyopharm Reveals 2025 Financials, Highlights Company

    12 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-company-progress-302685810.html

    PR NEWSWIRE
    12 Feb 2026
    Share Share
    Karyopharm Previews 2025 Revenue, Reiterates 2026 Guidance
    Karyopharm Previews 2025 Revenue, Reiterates 2026 Guidance

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-announces-preliminary-unaudited-2025-revenue-and-reiterates-expectation-of-delivering-potentially-transformative-phase-3-data-in-2026-302658039.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Malaysia Approves Antengene's XPOVIO for DLBCL Treatment
    Malaysia Approves Antengene's XPOVIO for DLBCL Treatment

    16 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-expands-xpovio-indications-in-malaysia-with-approval-in-diffuse-large-b-cell-lymphoma-302643379.html

    PR NEWSWIRE
    16 Dec 2025
    Share Share
    Karyopharm Reveals Q3 2025 Financials And Company Advancements
    Karyopharm Reveals Q3 2025 Financials And Company Advancements

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-reports-third-quarter-2025-financial-results-and-highlights-recent-company-progress-302601720.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Karyopharm Completes Ph3 SENTRY Trial Enrollment in Myelofibrosis
    Karyopharm Completes Ph3 SENTRY Trial Enrollment in Myelofibrosis

    10 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-announces-completion-of-enrollment-in-the-phase-3-sentry-trial-in-myelofibrosis-302551682.html

    PR NEWSWIRE
    10 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.